Lumos Pharma Inc. Watch

EX-2.2

from 8-K 25 pages Contingent Value Right Agreement

12/34/56

EX-2.1

from 8-K 81 pages Agreement and Plan of Merger Among Dpv Parent, Inc., Dpv Mergersub, Inc. and Lumos Pharma, Inc. Dated as of October 22, 2024

12/34/56

EX-2.1

from 8-K 3 pages Amendment No. 1 to Agreement and Plan of Merger and Reorganization

12/34/56

EX-2.1

from DEFA14A 3 pages Amendment No. 1 to Agreement and Plan of Merger and Reorganization

12/34/56

EX-2.2

from 8-K 10 pages Support Agreement

12/34/56

EX-2.2

from DEFA14A 10 pages Support Agreement

12/34/56

EX-2.1

from DEFA14A 34 pages Agreement and Plan of Merger and Reorganization Among: Newlink Genetics Corporation, a Delaware Corporation; Cyclone Merger Sub, Inc., a Delaware Corporation; and Lumos Pharma, Inc., a Delaware Corporation Dated as of September 30, 2019

12/34/56

EX-2.1

from 8-K 34 pages Agreement and Plan of Merger and Reorganization Among: Newlink Genetics Corporation, a Delaware Corporation; Cyclone Merger Sub, Inc., a Delaware Corporation; and Lumos Pharma, Inc., a Delaware Corporation Dated as of September 30, 2019

12/34/56

EX-2.1

from 8-K 16 pages Asset Purchase Agreement

12/34/56

EX-2.HTM

from 10-K 2 pages Certification

12/34/56

EX-2.HTM

from 8-K 1 page Newlink Enters Into an Agreement Converting Its $6 Million Forgivable Loan to a Royalty Interest

12/34/56

EX-2.HTM

from 8-K ~5 pages 2012 Target Bonus Awards

12/34/56